13573-28-9Relevant articles and documents
Nickel-Catalyzed Esterification of Amides Under Mild Conditions
Li, Jun-Fei,Wang, Yao-Fang,Wu, Yuan-Yuan,Liu, Wen-Jing,Wang, Jun-Wen
, p. 874 - 880 (2019/11/13)
Abstract: The use of ligands to adjust the catalytic activity of the catalyst for esterification of amides is challenge in organic chemistry. In this paper, Nickel(II)-NHC-catalyzed the esterification reaction between N,N-di-Boc amide and alcohols at room temperature have been demonstrated. The imidazolium salt bearing a hydroxyl functionalized side arm showed high effective catalytic activity in the activation of the amide N–C bond in air atmosphere. Graphic Abstract: [Figure not available: see fulltext.].
Polycyclic Sulfoximines as New Scaffolds for Drug Discovery
Borst, Mark L. G.,Ouairy, Cécile M. J.,Fokkema, Sander C.,Cecchi, Alessandro,Kerckhoffs, Jessica M. C. A.,De Boer, Vincent L.,Van Den Boogaard, Peter J.,Bus, Rutger F.,Ebens, Rijko,Van Der Hulst, Rob,Knol, Joop,Libbers, Rob,Lion, Zhou M.,Settels, Bart W.,De Wever, Ellen,Attia, Khaled A.,Sinnema, Piet-Jan,De Gooijer, Jesse M.,Harkema, Karen,Hazewinkel, Marieke,Snijder, Susan,Pouwer, Kees
supporting information, p. 335 - 343 (2018/05/14)
The design and synthesis of three novel polycyclic scaffolds containing sulfoximines are presented in this work, which exemplify that sulfoximines represent a real opportunity for the discovery of new drug candidates. Additionally, the structures present at least two points of diversification and contain a high level of sp3-character, hence being very interesting 3D scaffolds. The compounds synthesized were added to the compound collection of the European Lead Factory.
SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY
-
Page/Page column 40; 42; 138, (2017/02/09)
The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.